Analyze Diet

European journal of mass spectrometry.

Periodical
Chemistry Techniques
Analytical
Mass Spectrometry
Publisher:
IM Publications,. London, U.K. : SAGE Publishing (2017)
Frequency: Bimonthly
Country: England
Language: English
Start Year:2000 -
ISSN:
1469-0667 (Print)
1751-6838 (Electronic)
1469-0667 (Linking)
Impact Factor
1.3
2023
NLM ID:101124748
(OCoLC):44845933
Coden:EJMSCL
Classification:W1 EU72DHLS
Tracking main environmental factors masking a minor steroidal doping effect using metabolomic analysis of horse urine by liquid chromatography-high-resolution mass spectrometry.
European journal of mass spectrometry (Chichester, England)    May 18, 2019   Volume 25, Issue 3 339-353 doi: 10.1177/1469066719839034
Stojiljkovic N, Leroux F, Bubanj S, Popot MA, Paris A, Tabet JC, Junot C.There is an urgent need to implement holistic and untargeted doping control protocols with improved discriminatory power, compared to conventional methods that only target doping agents. Metabolomics, which aims to characterize all metabolites present in biological matrices, could fulfill this need. In this context, the aim of this study was to evaluate the impact of environmental factors on the ability to obtain a metabolic signature of stanozolol administration in horse doping situation. Urine samples from 16 horses breeded in two different places were collected over a one-year period, befor...
Detection of peginesatide in equine serum using liquid chromatography-tandem mass spectrometry for doping control purposes.
European journal of mass spectrometry (Chichester, England)    September 14, 2012   Volume 18, Issue 4 407-412 doi: 10.1255/ejms.1189
Möller I, Thomas A, Wingender A, Machnik M, Schänzer W, Thevis M.Erythropoietin (EPO) and its recombinant analogues are suspected to be illicitly administered to horses for performance enhancing purposes and, consequently, prohibited in equine sports. Recently, a new erythropoiesis-stimulating agent, peginesatide (Omontys, formerly referred to as Hematide), belonging to the upcoming class of EPO-mimetic peptides, received approval for the treatment of anaemia in humans with chronic kidney disease on dialysis. As the pegylated dimeric peptide of approximately 45 kDa without sequence homology to EPO is not detectable by conventional EPO detection assays, spec...